Study S000935

A Phase IIIb, Open-label, Pragmatic Study Evaluating Initiation Strategies for Survodutide, Including de Novo Use and Switching From Semaglutide or Tirzepatide, in Participants With Overweight/Obesity Without Diabetes Mellitus-SYNCHRONIZE® - START

ClinicalTrials.gov record

Registration

Registration: NCT07855900
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 350
Start: 2026-11-07
Primary completion: 2028-06-25
Lead sponsor: Boehringer Ingelheim
Conditions: Obesity
Interventions: COMBINATION_PRODUCT:Survodutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:U1111-1339-5379; REGISTRY:2026-527093-36-00

Registered primary outcomes

Percent change in body weight from baseline to Week 52 [At baseline and Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.